Paratek Pharmaceuticals (NASDAQ:PRTK) PT Lowered to $20.00

Paratek Pharmaceuticals (NASDAQ:PRTKGet Rating) had its price target decreased by investment analysts at HC Wainwright from $22.00 to $20.00 in a research report issued on Friday, The Fly reports.

PRTK has been the topic of several other research reports. StockNews.com raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 18th. BTIG Research reduced their price objective on shares of Paratek Pharmaceuticals from $34.00 to $30.00 in a research note on Monday, April 11th. Finally, WBB Securities raised shares of Paratek Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research note on Thursday, February 10th.

Shares of NASDAQ PRTK traded down $0.04 on Friday, hitting $2.12. The company’s stock had a trading volume of 3,616 shares, compared to its average volume of 705,825. Paratek Pharmaceuticals has a 12-month low of $2.03 and a 12-month high of $11.23. The company has a market capitalization of $115.50 million, a price-to-earnings ratio of -1.83 and a beta of 1.57. The stock has a 50 day moving average of $2.87 and a 200-day moving average of $3.89.

Paratek Pharmaceuticals (NASDAQ:PRTKGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). During the same quarter in the previous year, the company posted ($0.39) earnings per share. On average, sell-side analysts forecast that Paratek Pharmaceuticals will post -0.7 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA raised its stake in Paratek Pharmaceuticals by 378.5% during the third quarter. BNP Paribas Arbitrage SA now owns 7,967 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 6,302 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Paratek Pharmaceuticals during the fourth quarter worth approximately $56,000. Citigroup Inc. raised its stake in Paratek Pharmaceuticals by 70.7% during the fourth quarter. Citigroup Inc. now owns 14,664 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 6,075 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Paratek Pharmaceuticals during the fourth quarter worth approximately $76,000. Finally, Summit Global Investments purchased a new position in Paratek Pharmaceuticals during the third quarter worth approximately $90,000. 59.46% of the stock is currently owned by institutional investors.

Paratek Pharmaceuticals Company Profile (Get Rating)

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Read More

The Fly logo

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.